Alimera Sciences Appoints Steven T. Gill to the Newly Created Position of Vice President, Thought Leader Engagement
Alimera Sciences, Inc. (ALIM)
Last alimera sciences, inc. earnings: 4/29 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.alimerasciences.com/investor-relations
Company Research
Source: GlobeNewswire
ATLANTA, March 31, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has appointed Steven T. Gill as Vice President, Thought Leader Engagement. Mr. Gill rejoins Alimera from Novartis US where he was Associate Director, Thought Leader Liaison. In this newly created position at Alimera, Mr. Gill will have the responsibility to advocate for Alimera with physician and professional societies, further driving Alimera’s mission to be invaluable to patients, physicians and partners concerned with retinal health. He will focus on leading a team that will improve customer access by building long term relationships with physicians and key opinion leaders. “We are extremely pleased to welcome Steve back to Alimera in this new role intended to elevate our advocacy among key opinion leaders and drive increased peer-to-peer engage
Show less
Read more
Impact Snapshot
Event Time:
ALIM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALIM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALIM alerts
High impacting Alimera Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
ALIM
News
- Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences [Yahoo! Finance]Yahoo! Finance
- Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress ConferencesGlobeNewswire
- Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update [Yahoo! Finance]Yahoo! Finance
- Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate UpdateGlobeNewswire
- Alimera Sciences, Inc. (NASDAQ: ALIM) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
ALIM
Earnings
- 3/7/24 - Miss
ALIM
Sec Filings
- 4/29/24 - Form 10-K/A
- 4/2/24 - Form 4
- 3/13/24 - Form 4
- ALIM's page on the SEC website